 TCR2 Therapeutics is a company developing two lead oncology drug candidates targeting mesothelin, a protein expressed on different tumors. Its lead candidate gavo-cel, or TC-210, has presented strong data so far in different solid tumors, including tumor regression in 94 of evaluable patients and a manageable safety profile. 